Motixafortide
As of the edition of 20 October 2026, Motixafortide is a protein: marketed, first approved in 2023 (US); acts on CXCR4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Protein
- Brand name
- Aphexda
- First approved
- 8 September 2023 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ayrmid Pharma
- Registered trials
- 23, 4 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Inherited and neonatal; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Motixafortide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CXCR4 | C-X-C chemokine receptor type 4 | P61073 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 2 | 0 |
| Phase 2 | 14 | 7 | 2 | 4 |
| Phase 3 | 2 | 0 | 2 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 23 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| BioLineRx | Originator and Lead sponsor of trials | 2013 to now |
| Ayrmid Pharma | Acquired holder | 2025 to now |